Merz Therapeutics, a subsidiary of the Frankfurt-based Merz, has entered into an agreement to acquire two marketed drugs from the NASDAQ-listed US company Acorda Therapeutics. This deal is expected to significantly contribute to Merz Therapeutics' accelerated growth strategy.

Jörg Bergler, COO of the Merz Group, stated, "The intended investment perfectly aligns with Merz Therapeutics' growth strategy, expanding our portfolio in movement disorders and neurodegeneration, and strengthening our market position in North America. We believe that acquiring these two drugs, one for treating OFF phases of Parkinson's disease (PD) and the other for walking disorders in multiple sclerosis, will benefit both healthcare providers and patients."

The acquisition process is anticipated to be completed through a court-structured sale process under the US Bankruptcy Code, with Merz Therapeutics submitting the opening bid. The proposed purchase price is $185 million, and the sale is expected to be finalized in June 2024, subject to court approval.

For the family-owned Merz, headquartered in Frankfurt, this investment in a US company marks the third within just over a decade and the second in a NASDAQ-listed company. "Merz has experienced significant growth in recent years, both organically and through strategic acquisitions, especially in North America. As a German-based global company, we have substantial experience in acquiring and integrating companies or products and are keenly interested in innovative acquisitions, particularly in North America," said Jörg Bergler.

Stefan König, CEO of Merz Therapeutics, emphasized, "As a patient-focused, innovative company, we recognize our responsibility to further support Acorda Therapeutics' established and innovative therapies. This acquisition presents an optimal opportunity for portfolio expansion, supporting our ambitions in key therapeutic areas."

 

Source: businesswire.com

Report Abuse